MEDICAL FEE DISPUTE RESOLUTION FINDINGS AND DECISION

GENERAL INFORMATION

Requestor Name

Respondent Name

Memorial Compounding Pharmacy

Protective Insurance Company

MFDR Tracking Number

Carrier's Austin Representative

M4-18-2915

Box Number 17

MFDR Date Received

April 16, 2018

REQUESTOR'S POSITION SUMMARY

<u>Requestor's Position Summary</u>: "These medications do not require preauthorization therefore do not need a retrospective review."

Amount in Dispute: \$798.06

RESPONDENT'S POSITION SUMMARY

Respondent's Position Summary: "In review of the medical billing for date of service 11/28/17 and related evidence it was determined the charges in dispute were appropriately denied with claim adjustment reason code (50: Services not Deemed 'Medically Necessary' by payer) based on retrospective utilization review conducted by Richard S. Kaplan, MD. The original DWC-66 billing forms were received on 12/5/17. ON 12/20/17, a copy of the adverse determination was also sent to the injured employee and prescribing doctor. The EOR denial was issued to Memorial Compounding on 01/22/18."

Response Submitted by: CorVel

SUMMARY OF FINDINGS

Dates of Service	Disputed Services	Amount In Dispute	Amount Due
November 28, 2017	Pharmaceutical Compound	\$798.06	\$798.06

FINDINGS AND DECISION

This medical fee dispute is decided pursuant to Texas Labor Code §413.031 and applicable rules of the Texas Department of Insurance, Division of Workers' Compensation.

Background

- 1. 28 Texas Administrative Code §133.240 sets out the procedures for payment, denial, or reduction of a medical bill.
- 2. 28 Texas Administrative Code §133.307 sets out the procedures for resolving medical fee disputes.
- 3. 28 Texas Administrative Code §134.502 sets out the procedures for pharmaceutical benefits.

- 4. 28 Texas Administrative Code §134.503 sets out the fee guidelines for pharmaceutical services.
- 5. The insurance carrier reduced payment for the disputed services with the following claim adjustment codes:
 - Notes: "Except as provided in subsection (f)(1) of this section, drugs that do not require preauthorization are subject to retrospective review for medical necessity in accordance with §133.230 of this title.
 - 50 Service not Deemed 'Medically Necessary' by payer.

Issues

- 1. Is this dispute subject to dismissal based on medical necessity?
- 2. Is Memorial Compounding Pharmacy (Memorial) entitled to reimbursement of the disputed compound?

Findings

1. Memorial is seeking reimbursement for a compound dispensed on November 28, 2017. Per submitted explanation of benefits and CorVel's position statement on behalf of Protective Insurance Company for this dispute, the pharmacy bill was received by the insurance carrier on December 5, 2017. Protective Insurance Company denied the compound based on medical necessity on January 22, 2018. This date is more than 45 days after the date the bill was received.¹

The division notes that Protective Insurance Company failed to present a denial for medical necessity within 45 days from the date it received the complete pharmacy bill.² Therefore, the division finds that this dispute is not subject to dismissal based on medical necessity.

- 2. For the reasons above, the division finds that Memorial is eligible for reimbursement of the compound in question. 28 Texas Administrative Code §134.503 applies to the compound in dispute and states, in pertinent part:
 - (c) The insurance carrier shall reimburse the health care provider or pharmacy processing agent for prescription drugs the lesser of:
 - (1) the fee established by the following formulas based on the average wholesale price (AWP) as reported by a nationally recognized pharmaceutical price guide or other publication of pharmaceutical pricing data in effect on the day the prescription drug is dispensed:
 - (A) Generic drugs: ((AWP per unit) x (number of units) x 1.25) + \$4.00 dispensing fee per prescription = reimbursement amount;
 - (B) Brand name drugs: ((AWP per unit) x (number of units) x 1.09) + \$4.00 dispensing fee per prescription = reimbursement amount;
 - (C) When compounding, a single compounding fee of \$15 per prescription shall be added to the calculated total for either paragraph (1)(A) or (B) of this subsection; or
 - (2) notwithstanding §133.20(e)(1) of this title (relating to Medical Bill Submission by Health Care Provider), the amount billed to the insurance carrier by the:
 - (A) health care provider; or
 - (B) pharmacy processing agent only if the health care provider has not previously billed the insurance carrier for the prescription drug and the pharmacy processing agent is billing on behalf of the health care provider.

The compounds in dispute were billed by listing each drug included in the compound and calculating the charge for each drug separately as required by 28 Texas Administrative Code §134.502(d)(2). Reimbursement is calculated as follows:

¹ 28 Texas Administrative Code §133.240(a)

² State Office of Risk Management v. Lawton, 295 S.W.3d 646 (Tex. 2009), https://caselaw.findlaw.com/tx-supreme-court/1388209.html

Drug	NDC	Generic(G) /Brand(B)	Price /Unit	Units Billed	AWP Formula	Billed Amt	Lesser of AWP and Billed
Flurbiprofen	38779036209	G	\$36.58	6	\$274.35	\$219.48	\$219.48
Meloxicam	38779274601	G	\$194.67	0.18	\$43.80	\$35.04	\$35.04
Mefenamic Acid	38779066906	G	\$123.60	1.8	\$278.10	\$222.48	\$222.48
Baclofen	38779038809	G	\$35.63	3	\$133.61	\$106.89	\$106.89
Bupivacaine	38779052405	G	\$45.60	1.2	\$68.40	\$54.72	\$54.72
Ethoxy Diglycol	38779190301	G	\$0.34	3	\$1.28	\$1.03	\$1.03
Versapro Cream	38779252903	В	\$3.20	44.82	\$156.33	\$143.42	\$143.42
Fee	NA	NA	NA	NA	\$15.00	\$15.00	\$15.00
						Total	\$798.06

The total allowable reimbursement for the compound in dispute is \$798.06. This amount is recommended.

Conclusion

For the reasons stated above, the Division finds that the requestor has established that additional reimbursement is due. As a result, the amount ordered is \$798.06.

ORDER

Based on the submitted information, pursuant to Texas Labor Code Section 413.031 and 413.019 (if applicable), the division has determined the requestor is entitled to additional reimbursement for the disputed services. The division hereby ORDERS the respondent to remit to the requestor \$798.06, plus applicable accrued interest per 28 Texas Administrative Code §134.130, due within 30 days of receipt of this order.

Authorized Signature

		August 15, 2018		
Signature	Medical Fee Dispute Resolution Officer	Date		

YOUR RIGHT TO APPEAL

Either party to this medical fee dispute has a right to seek review of this decision in accordance with Rule §133.307, effective May 31, 2012, *37 Texas Register 3833*, applicable to disputes filed on or after June 1, 2012.

A party seeking review must submit a **Request to Schedule a Benefit Review Conference to Appeal a Medical Fee Dispute Decision** (form **DWC045M**) in accordance with the instructions on the form. The request must be received by the division within **twenty** days of your receipt of this decision. The request may be faxed, mailed or personally delivered to the division using the contact information listed on the form or to the field office handling the claim.

The party seeking review of the MFDR decision shall deliver a copy of the request to all other parties involved in the dispute at the same time the request is filed. **Please include a copy of the** *Medical Fee Dispute Resolution Findings and Decision* together with any other required information specified in 28 Texas Administrative Code §141.1(d).

Si prefiere hablar con una persona en español acerca de ésta correspondencia, favor de llamar a 512-804-4812.